Dyslipidemie a PCSK9 inhibitory - update indikačních a úhradových kritérií zaměřený prakticky
[Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria]
Vnitrni lekarstvi.
2022 Fall ;
68 (3) :
191-194.
Language Czech Country Czech Republic Media print
Document type Journal Article
Persistent link
https://www.medvik.cz/link/pmid36208951
PubMed
36208951
PII: 131953
- Keywords
- LDL‑ cholesterol, PCSK9-inhibitors, cardiovascular diseases, cardiovascular risk, diabetes mellitus, familial hypercholesterolemia, mixed dyslipidemia,
- MeSH
- Anticholesteremic Agents * therapeutic use MeSH
- Dyslipidemias * drug therapy MeSH
- Hypercholesterolemia * drug therapy MeSH
- Hypolipidemic Agents therapeutic use MeSH
- Cholesterol, LDL MeSH
- Humans MeSH
- PCSK9 Inhibitors MeSH
- Proprotein Convertase 9 MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anticholesteremic Agents * MeSH
- Hypolipidemic Agents MeSH
- Cholesterol, LDL MeSH
- PCSK9 Inhibitors MeSH
- PCSK9 protein, human MeSH Browser
- Proprotein Convertase 9 MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * MeSH
PCSK9 inhibitors are modern and effective hypolipidemic drugs for lowering LDL-cholesterol, which belong to the „biological therapy“. Their prescription is limited to specialized centers and to the fulfillment of other conditions set by SÚKL. This article lists the current valid criteria under which they can be indicated for reimbursement from public health insurance, and comments conditions and limitations in terms of the possibility of their fulfillment in clinical practice.
